Chemo-senolytic therapeutic potential against angiosarcoma
X. Wang, C. Y.-L. Chung, A. Yoshioka, S. Hashimoto, H. Jimbo, H. Tanizawa, S. Ohta, T. Fukumoto, K.-i. Noma
This study explores combining cisplatin and the senolytic agent ABT-263 to treat angiosarcoma, showing that low-dose cisplatin induces senescence, which is then eliminated by ABT-263, reducing chemotherapy side effects.
bioRxiv · Oct 19, 2023Cancer Biology